Next generation sequencing (NGS) is a technology that broadens the horizon of knowledge of several somatic pathologies, especially in oncological and oncohematological pathology. In the case of NHL, ...the understanding of the mechanisms of tumorigenesis, tumor proliferation and the identification of genetic markers specific to different lymphoma subtypes led to more accurate classification and diagnosis. Similarly, the data obtained through NGS allowed the identification of recurrent somatic mutations that can serve as therapeutic targets that can be inhibited and thus reducing the rate of resistant cases. The article’s purpose is to offer a comprehensive overview of the best ways of integrating of next-generation sequencing technologies for diagnosis, prognosis, classification, and selection of optimal therapy from the perspective of tailor-made medicine.
Non-Hodgkin's lymphomas (NHL) are malignant tumors that develop from lymphoid tissue. They are one of the most common malignancies and they represent one of the most complicated problems of ...oncohematology. The age group that is mostly affected by NHL in the Republic of Moldova is the patients over 60 years, and the disorder in most cases starts in lymph nodes. This study aims to determine the particularities of elderly patients with NHL with primary involvement of peripheral lymph nodes(l/n).
A retrospective study of a group of 78 NHL patients with primary lymph node involvement was performed. The average age of study participants ranged from 60 to 84 years.
NHL more often developed primarily in the peripheral l/n (84.7%), less frequently in the mediastinal l/n (6.4%) and abdominal l/n(8.9%). Aggressive NHL predominated (59.0%), but indolent NHL also developed quite frequently (41.0%), which were more frequent in cases of primary affection to the cervical l/n (47.4%), inguinal l/n(41.7%), and abdominal l/n(42.9%). The 5-year survival of NHL patients with primary lymph node involvement aged over 60 years was low and amounted to 31.2%;
NHL occurred more often in the peripheral lymph nodes (84.7%), less frequently in the mediastinum (6.4%), and abdominal lymph nodes (8.9%). The frequency of aggressive NHL was 59.0%. Indolent NHL was diagnosed in 41% of cases. The 5-year survival rate in the study group constitutes 31,2%, lower compared with younger patients treated in the same center.
ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA Buruiana, Sanda; Mazur, Minodora; Robu, Maria ...
Hematology, Transfusion and Cell Therapy,
November 2021, 2021-11-00, 2021-11-01, Letnik:
43
Journal Article
Recenzirano
Odprti dostop
Identification of hemostasis changes in patients with non-Hodgkin's lymphoma (NHL) and anticardiolipin antibodies (aCL).
The study included 83 patients (men-34, women-49) with a mean age of 63.2 ...years, with NHL, investigated complex, by research of lupus anticoagulant (LA) by Turbidimetry; antiβ2glycoprotein I IgG, IgM and aCL antibodies, by ELISA method. Hemostasis disorders were evaluated according to the type of NHL, stage, tumor size.
aCL were detected in 10 (12%) patients: 6 patients with aggressive type lymphoma and 4 patients with indolent type lymphoma, with advanced stage B cell NHL in 60%, mean age 52.8 years. LA was present in 80% of cases, unlike aCL IgG antibodies (10%) and antiβ2glycoprotein I IgG (10%). Hemostasis disorders were found in 6 (60%) patients: thrombotic events-at 4 (40%) patients with Mantle cell lymphoma (1 patient), Small lymphocytic lymphoma (1 patient), lymphoblastic lymphoma (2 patients). Local stage (I and II) of the lymphoma was in 75%, but with a large size of the tumor (> 11 cm), and hemorrhage at 2 (20%) patients with stage IV Small lymphocytic lymphoma, in which immune thrombocytopenia developed.
The presence of antiphospholipid antibodies, in particular of lupus anticoagulant, advanced age, generalized stage, and large tumor size are risk factors for the development of hemostasis diseases in NHL patients, especially thrombosis.
Background: Non-Hodgkin’s lymphomas (NHL) are malignant tumors that develop from lymphoid tissue. Primary lymph node (LN) involvement is the most common localization (52-70%). The integration of ...Rituximab (R) in the NHL treatment represented a turning point. The aim of this study was to evaluate the therapeutic impact of the use of R in combination with conventional polychemotherapeutic (PChT) in the treatment of nodal onset NHL. Material and methods: A descriptive cohort study was performed on 80 patients diagnosed with NHL. Results: In the study participated: men – 39(48.8%), women – 41(51.2%). The mean age of the patients was 56.09 ± 13.6 years. The onset of NHL occurred in peripheral l/n in 85.0% of cases, in mediastinal LN – 7.5%, and abdominals in 7.5%. Stages I-II were identified in 21(26.2%) patients, stages III-IV in 59(73.8%) cases. Aggressive NHLs were diagnosed in 54(67.5%) patients, indolent NHLs in 26(32.5%) cases. In 61(76.3%) patients, first-line R+PChT treatment was applied – group 1(G1), and in 19(23.8%) cases conventional PChT was applied – group 2(G2). The overall response rate (ORR) in G1 was 86.8%, in G2 – 63.1%. Complete remissions (CR) were obtained in G1 in 63.9% of patients, in G2 – 47.3% of cases. Progression-free survival (PFS) in G1 had a median of 20 months, and in G2 the median was 12 months (p <0.05). Conclusions: The use of Rituximab increased the ORR rate (86.8% vs 63.1%), the frequency of CR (63.9% vs 47.3%) and PFS (20 months vs 12 months (p <0.05).
Non-Hodgkin lymphomas (NHL) are a diverse group of malignant disorders arising from abnormal lymphatic tissue proliferation. Accurate NHL prognosis prediction is crucial for treatment guidance and ...better patient outcomes. In recent years, integrating molecular biology markers into classic prognostic scores (PS), or developing new PS entirely based on cytogenetic and molecular biology markers, has become increasingly popular. Although these refined scores offer higher sensitivity than traditional ones, their widespread adoption is hindered by the high costs they impose on healthcare systems. The aim of this study is to evaluate the utility of conventional based on biological and nutritional indexes PS in predicting overall survival (OS) in patients with nodal NHL.
The study evaluated 76 patients diagnosed with nodal NHL. Various prognostic scores were calculated based on established references, including the combined index of hemoglobin, albumin, lymphocyte, and platelet (HALP), the Platelet to Lymphocyte Ratio (PLR), the Neutrophil to Lymphocyte Ratio (NLR), the albumin/globulin ratio (A/G), and the Charlson comorbidity index (CCI).
Among the enrolled patients, 66 were diagnosed with B cell NHL and 10 with T cell NHL. The patient's age ranged from 22 to 83 years, with a mean age of 58. The most common sites of primary lymph node (LN) involvement were peripheral LN (84.61%), mediastinal LN (10.26%), and abdominal LN (5.13%). Aggressive NHLs were diagnosed in 73.07% of patients, while 26.93% had indolent NHL. Receiver Operating Characteristic (ROC) analysis revealed that the HALP score showed the highest sensitivity in predicting OS, with an area under the curve (AUC) of 0.652 (P=0.026). The CCI followed closely with an AUC of 0.635 (P=0.043), while the PLR (AUC=0.625), NLR (AUC=0.605), and A/G (AUC=0.588) scores demonstrated slightly lower sensitivities with P-values >0.05.
Among the evaluated prognostic tests, the HALP score and CCI demonstrated the highest sensitivity in predicting overall survival among NHL patients. These findings highlight the potential value of these scores in prognostication and patient management.
PDF
